The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
The FDA has approved a sublingual film formulation of the alpha-2 adrenergic receptor agonist dexmedetomidine (Igalmi — BioXcel Therapeutics) for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
Article code: 5056a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.